Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Pluristem’s PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study

January 22, 2018 By Cade Hildreth, Founder & President Leave a Comment

PLX cells exhibit anti-proliferative effect on a wide range of human cancer cell types
Pre-clinical study results show statistically significant reduction in tumor size as well as complete tumor remission in 30% of treated recipients

HAIFA, Israel, Jan. 12, 2018 — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced the publication of a peer-reviewed article in the journal Scientific Reports, from the publisher of Nature, titled, “Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF‑α and IFN‑γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models.”

The article is based on studies which examined the effect of PLX cells that had been induced with tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ), on the proliferation of over 50 lines of human cancerous cells. The induction of the cells was carried out by adjusting their manufacturing process in order to transiently alter their secretion profile. [Read more…]

Pluristem Gets Accelerated Approval Pathways in Top 3 Healthcare Markets – U.S., Europe, Japan

December 7, 2017 By Cade Hildreth, Founder & President Leave a Comment

Cell therapy was recently described as “One of the most promising new fields of science and medicine,” by FDA Commissioner Scott Gottlieb. He went on to state that cell therapy and regenerative medicine “…hold significant promise for transformative and potentially curative treatments for some of humanity’s most troubling and intractable maladies.” In the FDA statement issued August 28th, Gottlieb also revealed that the U.S. regulator is looking improve upon its approval process for cell therapies. [Read more…]

Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study

November 27, 2017 By Cade Hildreth, Founder & President Leave a Comment

Patent relates to the use of Mesenchymal Stem Cells (MSCs) for muscle regeneration following muscle injury
Pivotal Phase III study to take place in U.S. and Europe to support recovery from hip fracture

HAIFA, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent titled, “Skeletal muscle regeneration using mesenchymal system cells.” This key patent, which has already been granted in Europe, Hong Kong and Israel, addresses the use of MSCs for skeletal muscle regeneration used either directly after, or shortly after, post-surgical muscle injury.

The Company received positive feedback from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for the proposed study design and endpoints of its Phase III trial for the treatment of muscle recovery following arthroplasty for hip fracture. This planned study was recently awarded an $8.7 million grant by the Horizon 2020 program, the European Union’s largest research and innovation program. If successful, Pluristem plans to use the study results to achieve marketing approval in both the U.S. and Europe. [Read more…]

Cynata Therapeutics Releases Investor Presentation Featuring Operational Progress

November 17, 2017 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 15 November 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to release a new investor presentation to be presented at a series of upcoming institutional investor meetings.

Paul Wotton (Cynata Chairman) and Ross Macdonald (Cynata CEO) will be meeting with a series of new and existing institutional investors prior to the upcoming AGM on November 17.

Cynata Therapeutics provides investors with excellent exposure to a rapidly growing regenerative medicine and stem cell sector via its patented CymerusTM technology, a platform able to manufacture mesenchymal stem cells (MSCs) at a commercial scale. The new investor presentation highlights Cynata Therapeutics’ compelling investment case and provides information about the Company’s progress. [Read more…]

Enrollment of First Cohort Completed with Eighth Participant Dosed in Cynata’s World First Clinical Trial

November 15, 2017 By Cade Hildreth, Founder & President Leave a Comment

MELBOURNE, Australia, Nov. 15, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001. [Read more…]